Ionis Pharmaceuticals, Inc.
As of Oct 22, 2026, Ionis Pharmaceuticals is in Stage 4, the downtrend phase, now in week 15 (since Jul 15, 2026). It closed at $43.91, 49.2% below its 52-week high and below its 200-day average, which is falling.
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is IONS early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
IONS among Biotechnology311th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …311 | IONS | Stage 4 · wk 15 | 29 | −0.0% |
Ionis Pharmaceuticals: quick answers
What stage is Ionis Pharmaceuticals in?
As of Oct 22, 2026, Ionis Pharmaceuticals (IONS) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 15, 2026 and is in week 15. What the four stages mean
Is Ionis Pharmaceuticals in an uptrend?
No. Ionis Pharmaceuticals is in a Stage 4 downtrend. It trades 35.3% below its 200-day average, which is falling.
How far is Ionis Pharmaceuticals from its 52-week high?
Ionis Pharmaceuticals closed at $43.91 on Oct 22, 2026, 49.2% below its 52-week high of $86.50. Its 52-week low is $42.38.
How has Ionis Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Ionis Pharmaceuticals is down 38.7% over the past year and down 44.9% so far in 2026.
Which sector and industry is Ionis Pharmaceuticals in?
Ionis Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.